An Assessment of Radioimmunoassay Procedures for Determination of Anti-Acetylcholine Receptor Antibodies in the Sera of Patients with Myasthenia Gravis
Free accessResearch articleFirst published online May, 1981
An Assessment of Radioimmunoassay Procedures for Determination of Anti-Acetylcholine Receptor Antibodies in the Sera of Patients with Myasthenia Gravis
A reproducible radioimmunoassay procedure for the determination of anti-acetylcholine receptor antibodies in the sera of patients with myasthenia gravis is described and examined in detail. The assay combines features of a number of methods previously outlined and allows repeat determinations of antibody titre in a given myasthenic serum sample with coefficient of variation 6%. The mean ± standard deviation for normal human serum anti-acetylcholine receptor antibodies was found by this procedure to be 0·024 ± 0·033 nmol/l α-bungarotoxin binding sites whereas the range for myasthenic patients was 0–139·14 nmol/l with a mean value of 7·55 nmol/l α-bungarotoxin binding sites.
References
1.
SimpsonJA. Myasthenia gravis: A personal view of pathogenesis and mechanism Part 2. Muscle and Nerve1978; 1: 151–6.
2.
LindstromJMSeyboldMELennonVAWhittinghamSDuaneDD. Antibody to acetylcholine receptor in myasthenia gravisNeurology1976; 26: 1054–9.
3.
LefvertAKBergstromKMatellGOstermanPOPirskanenR.Determination of acetylcholine receptor antibody in myasthenia gravis: Clinical usefulness and pathogenic implications. J Neurol Neurosurg Psychiat1978; 41: 394–403.
4.
BarkasTHarrisonRLuntGGStephensonFABehanPOSimpsonJA. Acetylcholine receptor antibody titres in myasthenia gravis. In: BehanPORoseClifford A. eds. Progress in neurological research. Tunbridge Wells: Pitman Medical Press, 1979: 169–74.
5.
VincentANewsom-DavisJ.Bungarotoxin and anti-acetylcholine receptor antibody binding to the human acetylcholine receptor. Adv Cytopharmacol1979; 3: 269–78.
6.
CarterBHarrisonRLuntGGBehanPO. Simpson JA. Anti-acetylcholine receptor antibody titres in the sera of myasthenia patients treated with plasma exchange combined with immunosuppressive therapy. J Neurol Neurosurg Psychiat1980; 43: 397–402.
7.
AlmonRRAppelSH. Serum acetylcholine receptor antibodies in myasthenia gravis. Ann N Y Acad Sci1976; 274: 235–43.
8.
LindstromJ.An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopath1977; 7: 36–43.
9.
MonnierVMFulpiusBW. A radioimmunoassay for the quantitative evaluation of anti-human acetylcholine receptor antibodies in myasthenia gravis. Clin Exp Immunol1977; 29: 16–22.
10.
Newsom-DavisJPinchingAJVincentAWilsonSG. Function of circulating antibody to acetylcholine receptor in myasthenia gravis. Investigation by plasma exchange. Neurology1978; 28: 266–72.
StevensonCTDorringtonKJ. The recombination of dimers of immunoglobulin peptide chains. Biochem J1970; 118: 703–12.
13.
OuchterlonyONilssonLA. Immunodiffusion and immunoelectrophoresis. In: WeirDM, ed. Handbook of experimental immunology. Oxford: Blackwell, 1978; 1: 19–16.
14.
TomlinsonBEIrvingD.The numbers of limb motor neurons in the human lumbosacral cord throughout life. J Neurol Sci1977; 34: 213–9.
15.
DollyJO. Biochemistry of acetylcholine receptors from skeletal muscle In: TiptonKF, ed. International review of biochemistry. Baltimore: University Park Press, 1979; 26: 258–309.
16.
StephensonFAHarrisonRLuntGG. The isolation and characterisation of the nicotinic acetylcholine receptor from human muscle. Eur J Bioch1981; 115: 91–7.
17.
StephensonFA. Studies on the nicotinic acetylcholine receptor of human muscle. PhD, thesis, University of Bath.
